AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...

"Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases." "Nimble Therapeutics is committed to transforming ...

AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

(RTTNews) - AbbVie Inc. (ABBV), Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along with certain interim funding and milestone payments.

AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.

Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash. Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble ...

AbbVie has announced that it will be expanding its immunology pipeline by acquiring Nimble Therapeutics for $200m. The deal gives AbbVie access to Nimble’s lead asset, an investigational oral peptide ...